AI Article Synopsis
- * She was diagnosed with granulomatosis with polyangiitis, a serious autoimmune condition affecting her kidneys and lungs, confirmed by a kidney biopsy.
- * Treatment involved using rituximab and avacopan, which successfully reduced her symptoms and improved her overall health without any adverse reactions.
Article Abstract
A 78-year-old woman with a history of intractable otitis media presented with a fever, hearing impairment, thigh pain, and a skin rash. She had renal dysfunction, positive myeloperoxidase-antineutrophil cytoplasmic autoantibody, otitis media, and multiple nodules in both lungs. She was diagnosed with granulomatosis with polyangiitis, crescentic glomerulonephritis, and interstitial nephritis, which was confirmed in a kidney biopsy specimen. Induction therapy with rituximab and avacopan without glucocorticoids promptly resolved her fever and thigh pain and improved her auditory acuity and nodule in the right lung. The patient experienced no adverse effects with rituximab or avacopan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442917 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.3072-23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview.
Expert Rev Clin Pharmacol
November 2024
Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Introduction: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease which may result in serious pulmonary and kidney damage. Cyclophosphamide or rituximab and high-dose glucocorticoids significantly improved patient outcomes, but at the expense of severe complications. Moreover, many patients still relapse and bear a significant burden of both disease- and treatment-related complications.
View Article and Find Full Text PDFAvacopan in the treatment of refractory scleritis secondary to granulomatosis with polyangiitis: A case report.
Eur J Ophthalmol
October 2024
Uveitis and Scleritis Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Purpose: Avacopan is a novel C5a receptor inhibitor which was recently licensed for treatment of severe granulomatosis with polyangiitis (GPA) in the European Union and the United Kingdom. To the best of our knowledge, this is the first described case on initial ophthalmic outcomes in a patient with severe GPA and concurrent refractory scleritis treated with avacopan.
Case Description: We present a case of de novo scleritis in a 77-year-old male with a background of retinitis pigmentosa with Argus II implant in situ.
Effectiveness and Safety of Avacopan as a Combination Therapy with Glucocorticoids or Monotherapy in Patients with Microscopic Polyangiitis.
Intern Med
October 2024
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.
We herein report three cases of microscopic polyangiitis (MPA). Two patients were administered avacopan in combination with glucocorticoid (GC), whereas one patient was treated with avacopan monotherapy; none of the patients were co-administered either rituximab or cyclophosphamide. The doses of GC were successfully reduced after the introduction of avacopan in the two patients, and the serum C-reactive protein levels decreased in the patient treated with avacopan monotherapy.
View Article and Find Full Text PDFCrinkle-Cut Coronary Arteries in a Patient With Granulomatosis With Polyangiitis.
JACC Case Rep
September 2024
Department of Cardiology, Trinity Health Ann Arbor, Ann Arbor, Michigan, USA.
Article Synopsis
- - Granulomatosis with polyangiitis (GPA) is a rare vasculitis that primarily impacts small to medium blood vessels, often affecting the airways and kidneys.
- - Cardiac involvement in GPA is uncommon and typically doesn't present as the first symptom, making this case noteworthy.
- - A 44-year-old man experienced a heart issue that led to the diagnosis of GPA, showcasing vasculitis in the coronary arteries and myocarditis; he was treated with steroids, rituximab, and avacopan.
Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report.
CEN Case Rep
September 2024
Department of Nephrology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
The prognosis of anti-glomerular basement membrane (anti-GBM) nephritis, often accompanied by the presence of antineutrophil cytoplasmic antibodies (ANCA), is poor, and even with aggressive therapeutic approaches, kidney replacement therapy (KRT) is typically required. Here, we present a case of necrotizing crescentic glomerulonephritis in a patient double-seropositive for anti-GBM antibodies and ANCA who successfully achieved dialysis independence following aggressive treatment, including avacopan. The patient was a 77-year-old woman with rapidly progressive glomerulonephritis and double seropositivity for myeloperoxidase-ANCA and anti-GBM antibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!